Ergosterol

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

Retrieved on: 
Wednesday, April 17, 2024
Combination, Safety, Ophthalmology, Oncology, Dietary supplement, Polysaccharide, Immunotherapy, Partnership, Research, IND, CNS, Non-small-cell lung cancer, MSKCC, Lung cancer, Grifola frondosa, Therapy, Patient, Combination therapy, Edible, Myelodysplastic syndrome, Health, Triple-negative breast cancer, Clinical trial, MDS, Ergosterol, TNBC, US FDA, Investigational New Drug, Virginity, Pharmaceutical industry

The Investigational New Drug (IND) application for ABV-1519 proposed the clinical investigation of BLEX 404 as a Combination Therapy Drug with Chemotherapy.

Key Points: 
  • The Investigational New Drug (IND) application for ABV-1519 proposed the clinical investigation of BLEX 404 as a Combination Therapy Drug with Chemotherapy.
  • We believe that this collaboration leverages the respective strengths of both companies to accelerate the availability of this vital treatment to patients worldwide.
  • This licensing agreement exemplifies ABVC and OncoX's shared dedication to advancing medical science and improving patient care.
  • ABVC urges its shareholders to sign up on the Company's website for the latest news alerts: visit https://abvcpharma.com/?page_id=17707

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

Retrieved on: 
Wednesday, April 10, 2024
Use, BioLite, Ophthalmology, Polysaccharide, Pancreatic cancer, License, Dietary supplement, Partnership, IND, CNS, Non-small-cell lung cancer, CDMO, Knowledge, Investigational New Drug, Therapy, Royalty payment, Field, Edible, Myelodysplastic syndrome, Triple-negative breast cancer, MDS, Ergosterol, NSCLC, TNBC, US FDA, Pharmaceutical industry

The Investigational New Drug (IND) application proposed the clinical investigation of BLEX 404 as the primary active ingredient.

Key Points: 
  • The Investigational New Drug (IND) application proposed the clinical investigation of BLEX 404 as the primary active ingredient.
  • [1]
    "We are thrilled to announce that the term sheet for a potential groundbreaking licensing deal with OncoX has been successfully executed.
  • This licensing deal marks a significant milestone for ABVC and OncoX, affirming their commitment to excellence and shared vision for the future.
  • ABVC urges its shareholders to sign up on the Company's website for the latest news alerts; visit https://abvcpharma.com/?page_id=17707

ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars

Retrieved on: 
Tuesday, February 27, 2024
NSCLC, Therapy, Reflection nebula, Ophthalmology, Marketing, Investigational New Drug, Immune system, Myelodysplastic syndrome, Immunotherapy, Collateral damage, Shogun, FDA, Dietary supplement, US FDA, Polysaccharide, Nausea, Grifola frondosa, Hair loss, CDMO, Safety, MDS, Fatigue, CNS, TNBC, Edible, Ergosterol, Patient, Quality of life, Drug, Immunity, IND, Cancer

The Investigational New Drug (IND) application proposed the clinical investigation of BLEX 404 as the primary active ingredient.

Key Points: 
  • The Investigational New Drug (IND) application proposed the clinical investigation of BLEX 404 as the primary active ingredient.
  • The global cancer therapeutics market is expected to be worth around US$ 393.61 billion by 2032 from US$ 164 billion in 2022, growing at a CAGR of 9.20% from 2023 to 2032.
  • [4] Straits Research reports that the global botanical drug market size was valued at $163 million in 2021 and is expected to be valued at $3.2 billion.
  • The market is expected to grow at a CAGR of 39% during the forecast period (2022–2030).

Human medicines European public assessment report (EPAR): Posaconazole Accord, posaconazole, Date of authorisation: 25/07/2019, Revision: 8, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Coccidioidomycosis, Patient, Medical Subject Headings, Spore, Marketing, Amphotericin B, Chromoblastomycosis, Failure, Acute leukemia, INN, Immune system, Canker, Stomach, Risk, Infection, Bone marrow, Itraconazole, ATC, Refractory, Fungus, B cell, International, Fluconazole, Disease, Blood, Language, Neutropenia, MDS, Haematopoiesis, European Medicines Agency, Aspergillosis, Mycetoma, Syndrome, Tablet, Select, HSCT, Anatomy, AML, Ergosterol, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Posaconazole Accord, posaconazole, Date of authorisation: 25/07/2019, Revision: 8, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Posaconazole Accord, posaconazole, Date of authorisation: 25/07/2019, Revision: 8, Status: Authorised

International Cannabis Brand Cookies Launches New Product Combining Non-Psychedelic Mushrooms and THC

Retrieved on: 
Thursday, September 23, 2021
Alternative Medicine, Retail, Luxury, Health, Tobacco, Specialty, THC, Social media, Caps, Collection, CBN, Sale, Cannabinoid, Ergosterol, BED, CEO, Night, Entrepreneurship, Cordyceps, Breeding, Terpene, Cannabis, HEAD, Capsule, Relaxation, Medicinal plants

International cannabis brand Cookies today announced the debut of Caps by Cookies THC Capsules .

Key Points: 
  • International cannabis brand Cookies today announced the debut of Caps by Cookies THC Capsules .
  • Encapsulated to harness the entourage effect, Caps by Cookies THC Capsules provide a fully functional experience designed to expand the daily wellness routine.
  • Caps by Cookies THC Capsules are the next phase of expansion in the Caps by Cookies portfolio.
  • Cookies is more than a premiere cannabis company, it is an authentic brand with passionate fans all over the world.

Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer

Retrieved on: 
Tuesday, August 17, 2021
Psilocybin, Company, Universidad Central del Caribe, Organ transplantation, RVV, Substance abuse, Quality of life, CSE, Reperfusion injury, Infection, Therapy, Cancer, Biology, Patent Cooperation Treaty, Orphan drug, Acquisition, GLOBE, Intention, AKT2, Synthesis, Research, Central, Ischemia, AKT1, Agreement, Inflammation, Revive, Autoimmune hepatitis, Cyclin D1, Intellectual property, Mental health, Ergosterol, Clinical trial, GLE, UCC, Puerto Rico Science, Technology and Research Trust, Hypertension, Medicine, PARP, CEO, Hospital, Apoptosis, Breast, Liver disease, FDA, ROS, Disorder, COVID-19, Breast cancer, Technology, Drug development, Pharmaceutical industry

PCT/US2020/017053 /) titled, Biologically Active Ganoderma Lucidum Compounds and Synthesis of Anticancer Derivatives; Ergosterol Peroxide Probes for Cellular Localization.

Key Points: 
  • PCT/US2020/017053 /) titled, Biologically Active Ganoderma Lucidum Compounds and Synthesis of Anticancer Derivatives; Ergosterol Peroxide Probes for Cellular Localization.
  • Judeand UCC have characterized medicinal mushroom Ganoderma lucidum compounds with anti-cancer activity, specifically signicant activity against breast cancer, thus having the potential to treat the most aggressive types of breast cancers such as triple negative breast cancer and inammatory breast cancer.
  • Medicinal mushroom Ganoderma lucidum has been used in traditional Chinese medicine for more than two millennia.
  • Under the terms of the Agreement, Revive gained exclusive worldwide development and commercial rights to intellectual property ( International Patent Application No.